

28.(New) The array of claim 22, wherein said modified oligonucleotides have an average length of from about 80 to about 300 nucleotides.

29.(New) The array of claim 22, wherein said modified oligonucleotides have an average length of from about 100 to about 200 nucleotides.

30.(New) The array of claim 22, wherein oligonucleotides of each of said oligonucleotide compositions has a different sequence from oligonucleotides of any other oligonucleotide composition on the array.

31.(New) The array of claim 22, wherein each oligonucleotide composition comprises a population of identical oligonucleotides.

32.(New) The array of claim 22, wherein each oligonucleotide composition comprises a plurality of oligonucleotides that bind to a particular nucleic acid.

33.(New) The array of claim 22, wherein the number of oligonucleotide compositions on said array ranges from about 2 to about  $10^9$ . --

#### REMARKS

Claims 22-33 are pending in this application.

Claims 1-21 have been canceled, and claims 22-33 added, to more particularly point out and distinctly claim the invention. Claims which have not been amended have been reiterated for the convenience of the Examiner.

Support for new independent claim 22 can be found throughout the specification, and particularly at page 11, lines 1-7; page 38, Example 2 (lines 1-17) and page 10, lines 2-26.

Support for dependent claim 23 can be found at page 8, lines 11-15.

Support for dependent claim 24 can be found at page 11, lines 4-6.

Support for dependent claims 25 and 26 can be found throughout the specification, with an exemplary passage at page 10, lines 17-18.

Support for dependent claims 27-33 can be found in originally filed claims 13 and 4-9, respectively.

No new matter is added by any of the amendments.

### The Invention in General

The presently pending claims are directed to arrays with associated compositions of 1) oligonucleotides having increased acid stability; 2) where such modified oligonucleotides are associated on a substrate and 3) where the oligonucleotides of the compositions are designed so that each oligonucleotide composition will have approximately the same  $T_m$  as the other compositions on the array when bound with the target nucleic acid. These arrays have numerous advantages over arrays known in the art. These characteristics also allow the clearance of the target nucleic acids from the arrays of the invention, allowing the arrays to be reused. Compositions having constant  $T_m$  can also allow for the clearance of the target nucleic acids at a given temperature. The acid stability of the bound oligonucleotides allow the clearance of the target nucleic acids by subjecting the arrays to acidic conditions. In addition, the fact that each associated composition is designed to have approximately the same  $T_m$  with its target binding partner allows the array to be designed for use at a same specific stringency, e.g. high stringency to ensure selective hybridization or low stringency to identify related molecules.

The oligonucleotides of each composition also preferably have an end block to enhance exonuclease stability. This provides an exonuclease stability to allow the array to be directly contacted with target nucleic acids from biological sources, e.g., human tissue, without requiring purification to eliminate the exonucleases present in the samples.

### Restriction Requirement

In view of the restriction requirement, Applicants confirm election of Group I, claims 1-15, directed to an array comprising a plurality of modified oligonucleotides. The remaining claims have been

canceled without prejudice to renewal as being directed to nonelected subject matter. The new claims added herein claim the subject matter of Group I, as they are directed to an array comprising a plurality of modified oligonucleotides.

Objection to the Specification

The specification was objected to for failing to comply with 37 CFR 1.821 through 1.825. This objection has been rendered moot by the amendment to the specification at page 38, which adds the SEQ ID NO to the disclosed sequence in the specification.

Rejection of claims 1-9 and 15 under 35 USC §112, first paragraph

Claims 1-9 and 15 were rejected under §112, first paragraph for containing subject matter which was not described in the specification in a manner to allow one skilled in the art to practice the invention as described. This rejection is adverse as applied, and as may be applied to the presently pending claims, but is also rendered moot by the new claims. Specifically, Examiner rejected the claims as requiring undue experimentation to determine the modifications that would result in increased binding affinity of the oligonucleotides of the array of the invention. The currently pending claims specifically recite that the claims of the invention are all designed to have the same  $T_m$  with a specific target nucleic acid of interest. The design of oligonucleotides having the same  $T_m$  is sufficiently described in the specification to allow one skilled in the art to practice the invention as claimed without undue experimentation. Moreover, the 2' ribose modification and the end block are described at length, and would not require undue experimentation.

The acid stability of the molecules is experimentally demonstrated in the examples of the present application, as is determination of  $T_m$  for various binding pairs. Acid stability is described in Example 3 and 4, pages 38-40. Determination of  $T_m$  for various binding pairs is described in the specification at Example 2, page 38 lines 1-17.

Accordingly, Applicants respectfully request withdrawal of the §112, first paragraph rejection as it may be applied to pending claims 22-33.

Rejection under 35 USC §112, second paragraph

Claims 1-9 and 14-15 were also rejected under §112, second paragraph, for failing to particularly point out and distinctly claim that which is the subject matter of the invention. The rejection is traversed, but is rendered moot by the language of the presently pending claims.

Claim 22 claims an array having oligonucleotide compositions with oligonucleotides having 1) at least one nucleotide with a 2' ribose substitution and 2) approximately the same  $T_m$  with the target nucleic acid, be it RNA or DNA, as each of the other associated nucleic acids. Thus, the metes and bounds of the modifications of the oligonucleotides are clearly stated, the placement of the end block is clearly defined, and the properties of the oligonucleotides with respect to one another are clarified. Claim 23, which claims associated compositions of oligonucleotides having end blocks, now specifically recites that the an end block is either 5' or 3' of the test sequence of the nucleic acid.

Accordingly, Applicants respectfully request withdrawal of the §112, second paragraph rejections as they might apply to the presently pending claims.

Rejection of claims 1-9 and 14 under 35 USC §103(a)

Claims 1-9 and 14 stand rejected under §103 as obvious over U.S. Pat. No. 5,986,083 (hereafter "Dwyer") in view of WO 94/15619 (hereafter "Miller"), or over Dwyer and Miller in further view of U.S. Pat. No. 5,861,242 (hereafter "Chee"). These rejections are traversed as applied, and as they may be applied to the presently pending claims.

To establish a case of prima facie, three basic criteria must be met: 1) there must be some suggestion or motivation, either in the references themselves or in the knowledge generally available to one of ordinary skill in the art, to modify the reference or to combine reference teachings; 2) there must be a reasonable expectation of success and 3) the prior art reference (or references when combined) must teach or suggest all the claim limitations. MPEP §§2143-2143.03. The teaching or suggestion to make the claimed combination and the reasonable expectation of success must both be found in the prior art, and not based on applicant's disclosure. In re Vaeck, 947 F.2d 488, 20 USPQ2d 1438 (Fed. Cir.1991).

The presently pending claims are not prima facie obvious over the cited art, as the art does not meet all of the elements of prima facie obviousness. Specifically, the prior art does not teach each and

every limitation of the invention as claimed, and thus one skilled in the art would not have had motivation to combine all of the elements of the present invention.

Dwyer et al. are cited as describing modified oligonucleotides which exhibit nuclease stability and an enhanced binding affinity with complementary target nucleic acids. Dwyer et al. do not, however, describe 1) oligonucleotides having increased acid stability; 2) such modified oligonucleotides associated on a substrate and 3) designing the oligonucleotides of the compositions so that each oligonucleotide composition will have approximately the same  $T_m$  as the other compositions on the array with the target nucleic acid. Dwyer et al. also does not specifically describe oligonucleotides having an end block either 3' or 5' of the sequence of interest to enhance exonuclease stability of the oligonucleotide.

Miller et al. is cited as describing an oligonucleotide having a 2' modification to a 2'-O-alkyl. Although this is demonstrated in Miller to confer acid stability onto the molecule, Miller does not describe molecules on an array, associated compositions having approximately the same  $T_m$  for the intended nucleic acid targets, or an end block to enhance exonuclease stability.

Finally, Chee et al., which is cited as describing a high density array of oligonucleotides immobilized on a solid support, does not teach oligonucleotides having enhanced acid stability, enhanced nuclease stability, or compositions having approximately the same  $T_m$  for the intended nucleic acid targets.

Accordingly, as each and every limitation is not taught nor suggested by the references alone or in combination, the claims are not *prima facie* obvious over the cited art. The references do not teach or suggestion the claimed combination, and thus one skilled in the art would not be motivated to combine the elements of the present invention to obtain an array with the beneficial properties of the present invention. Applicants respectfully request withdrawal of the §103(a) rejection and allowance of the claims as presently pending.

### Conclusion

The presently pending claims have been amended or added to more distinctly claim the subject matter of the invention. The invention is sufficiently described in the specification to allow one skilled

in the art to practice the invention as claimed. Moreover, the claimed invention is not obvious over the cited art, as the art does not teach each and every element of the claimed invention and the combination would not prompt one skilled in the art to conceive of or practice the present invention. Accordingly, Applicants respectfully request allowance of the claims as pending.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: 3/21/00

By: Dianna L. DeVore

Dianna L. DeVore  
Registration No. 42,484

BOZICEVIC, FIELD & FRANCIS LLP  
285 Hamilton Avenue, Suite 200  
Palo Alto, California 94301  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231  
F:\DOCUMENT\OLIG\020\amend to oa of 12-23-99.wpd